Trial reportEuropean heart journal. Cardiovascular Imaging2025
Prognostic value of myocardial perfusion imaging in asymptomatic high-risk diabetic patients: 10-year follow-up of the prospective multicentre BARDOT trial.
Trial report in European heart journal. Cardiovascular Imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hunting for a coronary artery disease diagnosis in asymptomatic patients with diabetes mellitus: if, how and when.Cardiovascular diabetology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsPatients with type 2 diabetes mellitus (T2DM) are at high risk for coronary artery disease (CAD) related events and are often asymptomatic. The role of cardiac imaging in screening asymptomatic T2DM patients remains controversial, as existing studies are limited by short follow-up periods. Therefore, study aim was to provide long-term (10 years) outcome data of T2DM patients screened with cardiac imaging. METHODS AND
resultsA total of 400 asymptomatic high-risk T2DM patients without history of CAD underwent screening with Single Photon Emission Computed Tomography (SPECT). Abnormal SPECT was defined as Summed Stress Score ≥ 4 or Summed Difference Score ≥ 2. Patients were followed for all-cause mortality and major adverse cardiovascular events (MACE, cardiovascular mortality + myocardial infarction).The mean age was 63 ± 8 years; 69% were male. Diabetic end-organ damage was present in 87% of patients. Baseline SPECT was abnormal in 22% of patients. Median follow-up was 11.1 (8.8, 12.8) years. Abnormal SPECT was associated with higher all-cause mortality [hazard ratio (HR) 1.614, P = 0.029] and MACE (HR 2.024, P = 0.009). A normal SPECT was associated with a significantly better prognosis (all-cause mortality 1.9 vs. 3.1%/year, P = 0.016; MACE 1.2 vs. 2.3%/year, P = 0.010). In the small subgroup of patients with abnormal SPECT, the treatment strategy (revascularization vs. conservative) had no effect on event-free survival.
conclusionA normal SPECT was associated with an excellent long-term prognosis in high-risk T2DM patients. Hence, SPECT could serve as a valuable tool for advanced risk stratification in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.